CTOs on the Move

BioIntervene

www.biointervene.com

 
BioIntervene, Inc. is a preclinical-stage biopharmaceutical company committed to the discovery and development of effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. The Company was founded in 2014 based on insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene`s founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists. California, United States Read more at CB Insights: https://www.cbinsights.com/company/biointervene
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioIntervene raised $30M on 01/06/2020

Similar Companies

Partner Therapeutics

Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.

Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuraptive Therapeutics

Neuraptive is bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves.

Xcell Biosciences

Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing.

Hyasynth Bio

Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.